Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen open-label extension after the Frontiers Apheresis parent study
2023-503611-16-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pelacarsen in cardiac morbidity and lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Novartis. Primary endpoint: Safety and tolerability. Started Sep 2023; status: completed.
02
Drugs
pelacarsen
03
Conditions
cardiac morbiditylipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on 2023-503611-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503611-16-00.